Merck KGaA presses Versum investors to back its $5-9B acquisition bid
Category: #headlines  By Mateen Dalal  Date: 2019-03-06
  • share
  • Twitter
  • Facebook
  • LinkedIn

Merck KGaA presses Versum investors to back its $5-9B acquisition bid

Versum management rejected Merck KGaA’s all-cash offer in favor of rival Entegris’ January offer

Merck KGaA, based out of Darmstadt in Germany, has reportedly urged the shareholders of U.S. electronic materials company Versum Materials, to pressurize its management for considering Merck’s offered proposal for takeover against a rival bid.

In an open letter to the investors of Versum, Merck called on them to advise the Board of Versum that its shareholders would not be supporting an acquisition by Entegris owing to a superior proposal by the German pharmaceutical giant. It also informed the investors that an offer to directly engage with Versum for understanding the rationale behind the Board’s determination was not accepted.

Officials from Versum had not yet offered any comments on the reports, however the company has made known that it remains committed towards a no-cash merger with Entegris, which had been agreed to in January this year. Apparently, Merck’s unsolicited cash bid valued at $5.9 billion, which was a non-binding proposal made to Versum management and had not been put out to shareholders, was recently rejected by the company.

Reports confirm that Entegris had made an offer to acquire Versum Materials in January, in an agreed all-stock transaction that valued the equity of Versum at nearly $4 billion at the time. Their merger would lead to the creation of a substantially large chemical supplier to the currently under-pressure semiconductor industry.

Merck has supposedly disclosed that it is planning to keep the main Tempe, Arizona site of Versum as the U.S. hub for a combined electronic materials business in the country. It suggested that the premium valuation represented in its proposal is immediate and certain, without the need for achieving any synergies and without any of the substantial ongoing integration, market or operational risks reflected in the value of Entegris’ stock consideration.

One of the investors of Versum has indicated that if Merck wants to oust an existing deal agreed upon, it would need to give shareholders more assurance with regard to its offer.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Merck to acquire cancer drug maker Peloton Therapeutics for $1.05Bn
Merck to acquire cancer drug maker Peloton Therapeutics for $1.05Bn
By Mateen Dalal

The acquisition would help Merck strengthen its presence in the renal cell carcinoma space and support its cancer drug portfolio. U.S. pharmaceutical conglomerate, Merck & Co. Inc. has recently agreed to purchase Dallas based Peloton Therapeutic...

Ikea invests in India’s one-stop interior design platform Livspace
Ikea invests in India’s one-stop interior design platform Livspace
By Mateen Dalal

The interior design platform had raised over $70 million last year with investment from TPG Growth & Goldman Sachs. The investment is Ikea’s first such deal in India, however it isn’t the company’s dalliance in India’s ...

BioXcel unveils data from Phase 1 study of receptor agonist BXCL501
BioXcel unveils data from Phase 1 study of receptor agonist BXCL501
By Mateen Dalal

Sublingual administration of BXCL501 had achieved drug exposures that will be therapeutic for the acute treatment of agitation Reports confirm that BioXcel Therapeutics (BTI) has recently presented data from its Phase 1 pharmacokinetic (bioavailabil...